Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab with or without Tremelimumab and Radiation Therapy in Advanced Bladder Cancer
NCT03601455Phase 2Active, not recruiting
- Sponsor
- UCLA Jonsson Comprehensive Cancer Center
- Start
- Oct 2018
- Primary completion
- Jan 2027
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of durvalumab, tremelimumab in Urothelial Bladder Cancer (UBC), sponsored by UCLA Jonsson Comprehensive Cancer Center. Started Oct 2018; status: active, not recruiting.
02
Drugs
durvalumabtremelimumab
03
Conditions
Urothelial Bladder Cancer (UBC)
Beyond the preview
Go deeper on NCT03601455.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03601455.